NAT CANCER 润色咨询

Nature Cancer

出版年份：暂无数据 年文章数：187 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2024-03-15 ms4000000788024174 来自浙江省

    1

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-04-21 ms1000000589600011 来自瑞典

    他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2024-01-05 pxx20143837 来自四川省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：放疗;临床研究
    经验分享：非常难

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-09-10 shyhihihi 来自佛罗里达

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究
    经验分享：直接投稿（没有pre-submission inquiry）
    manuscript under consideration （2周左右）
    Editor Decision Started
    邮件通知送外审
    经验1 （中稿）：
    然后Manuscript under consideration（一个月左右）
    通知改稿
    重投Manuscript submitted
    Manuscript under consideration（2周左右）
    原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）
    一共历时3个多月，算是非常顺利的一次。
    ————————————
    经验二（拒稿）：
    Manuscript under consideration （13 days）
    Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-12-15 ms5000002124798802 来自浙江省

    1

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-11-09 ms4000000924673027 来自广东省

    请问under consideration21天了，是什么情况，需要催一下吗

    18

    展开18条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-12-11 ms9000000515592458 来自江苏省

    审稿速度:6.0 | 投稿命中率:5.0
    经验分享：11212

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-12-02 Tou gao小菜鸡 来自广东省

    偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究
    经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2022-11-11 ms3000000081429133

    偏重的研究方向：肿瘤
    经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗

    12

    展开12条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2193464, encodeId=6fbf21934646a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52df8775259, createdName=ms4000000788024174, createdTime=Fri Mar 15 17:34:49 CST 2024, time=2024-03-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2127391, encodeId=5629212e3914c, content=他们的presubmission inquiry不错。一天给结果。第一次williamhill asia 发了后邀请投稿不过被拒，转了Nat Comm现在等外审结果。现在第二篇还是邀请投稿，看看结果怎样。编辑总的来说态度不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Fri Apr 21 02:11:10 CST 2023, time=2023-04-21, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2179308, encodeId=a0ba21e9308b2, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：放疗;临床研究<br>经验分享：非常难, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=16c04779958, createdName=pxx20143837, createdTime=Fri Jan 05 00:01:35 CST 2024, time=2024-01-05, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2157041, encodeId=4361215e0411b, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：临床试验;癌症免疫治疗;癌症基础研究<br>经验分享：直接投稿（没有pre-submission inquiry）<br>manuscript under consideration （2周左右）<br>Editor Decision Started <br>邮件通知送外审<br>经验1 （中稿）：<br>然后Manuscript under consideration（一个月左右）<br>通知改稿<br>重投Manuscript submitted<br>Manuscript under consideration（2周左右）<br>原则上接收 （原则接收后还需要大概一个月左右时间提供原始数据等才会正式接收）<br>一共历时3个多月，算是非常顺利的一次。<br>————————————<br>经验二（拒稿）：<br>Manuscript under consideration （13 days）<br>Editor Decision Started（邮件通知不感兴趣，编辑部直接拒掉，哭~~~）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3f92397506, createdName=shyhihihi, createdTime=Sun Sep 10 22:25:02 CST 2023, time=2023-09-10, status=1, ipAttribution=佛罗里达), GetPortalCommentsPageByObjectIdResponse(id=2175141, encodeId=e52921e51419a, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=629c8513241, createdName=ms5000002124798802, createdTime=Fri Dec 15 18:49:39 CST 2023, time=2023-12-15, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2167579, encodeId=f560216e57988, content=请问under consideration21天了，是什么情况，需要催一下吗 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49456469753, createdName=ms4000000924673027, createdTime=Thu Nov 09 14:59:41 CST 2023, time=2023-11-09, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2174265, encodeId=d70021e426532, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：11212, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91c18827243, createdName=ms9000000515592458, createdTime=Mon Dec 11 14:22:29 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2172517, encodeId=5d8c21e251772, content=偏重的研究方向：癌症;癌症免疫治疗;癌症基础研究<br>经验分享：请问presubmission inquiry编辑回复邀请投稿送审机会大吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fb42104454, createdName=Tou gao小菜鸡, createdTime=Sat Dec 02 16:08:35 CST 2023, time=2023-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2099851, encodeId=e8aa209985137, content=偏重的研究方向：肿瘤<br>经验分享：投稿后Manuscript under consideration这个状态已经持续了10天了，有人知道啥时候有结论吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Fri Nov 11 11:32:57 CST 2022, time=2022-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2166002, encodeId=4b48216600264, content=投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=293e2062700, createdName=08021, createdTime=Wed Nov 01 03:12:29 CST 2023, time=2023-11-01, status=1, ipAttribution=宾夕法尼亚)]
    2023-11-01 08021 来自宾夕法尼亚

    投稿7天通知外审，20天正式送审（编辑出差），27天外审中。。。。。。。。。

    0

共76条页码: 1/8页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分